Can I read Efficacy and Safety of Rizatriptan Wafer for the Acute Treatment of Migraine on EtoBox?

Efficacy and Safety of Rizatriptan Wafer for the Acute Treatment of Migraine by SP Ahrens; MV Farmer; DL Williams; E Willoughby; K Jiang; GA Block; WH Visser; Rizatriptan Wafer Protocol 049 Study Group is a Medicine article available to read on EtoBox.

What is Efficacy and Safety of Rizatriptan Wafer for the Acute Treatment of Migraine about?

Rizatriptan is a potent, highly selective 5HT~1B/1D~ agonist with rapid onset of action for acute treatment of migraine. Rizatriptan wafer^1^ is a novel, freeze-dried dosage formulation of rizatriptan which rapidly disintegrates on the tongue, is swallowed with saliva, and may be taken without liquids. The efficacy and tolerability of rizatriptan wafer were examined in a placebo-controlled, double-blind, outpatient study in 555 migraineurs. The primary efficacy endpoint was pain relief at 2 h. From 30 min onwards, significantly more patients experienced pain relief and became pain-free after rizatriptan 10-mg wafer compared to placebo. At 2 h, the percentage of patients with pain relief was significantly higher after rizatriptan 10-mg wafer (74%), 5-mg wafer (59%) compared with placebo (28%). Rizatriptan 10-mg wafer was superior to rizatriptan 5-mg wafer on pain relief at 1.5 and 2 h ( p<0.05). Significantly more patients were pain-free at 2 h after rizatriptan 10-mg wafer (42%), 5-mg wafer (35%) compared with placebo (10%). Both doses of rizatriptan wafer were well tolerated. Rizatriptan wafer is a convenient, highly effective new formulation for acute treatment of migraine.

Who reads Efficacy and Safety of Rizatriptan Wafer for the Acute Treatment of Migraine?

Author

SP Ahrens; MV Farmer; DL Williams; E Willoughby; K Jiang; GA Block; WH Visser; Rizatriptan Wafer Protocol 049 Study Group

Publisher

John Wiley and Sons; SAGE Publications; Wiley (ISSN 0333-1024)

Published

1999

Language

EN

Field

Medicine (Health Sciences)